期刊
FRONTIERS IN IMMUNOLOGY
卷 6, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2015.00501
关键词
chemotherapy; dendritic cells; anti-tumor immunity; antigen-presenting cell; tumor-induced T cell dysfunction; immunogenic cell death
类别
资金
- Wilhelm Sander-Stiftung fur Krebsforschung
- Swiss National Science Foundation
- Krebsliga beider Basel
- Sassella-Stiftung
- Huggenberger-Bischoff Stiftung zur Krebsforschung
- Freiwillige Akademische Gesellschaft Basel
- SAKK/Amgen Research Grant
Professional antigen presenting cells (APCs), such as dendritic cells (DCs), are central to the initiation and regulation of anti-cancer immunity. However, in the immunosuppressive environment within a tumor APCs may antagonize anti-tumor immunity by inducing regulatory T cells (Tregs) or anergy of effector T cells due to lack of efficient costimulation. Hence, in an optimal setting, anti cancer drugs have the power to reduce tumor size and thereby may induce the release of tumor antigens and, at the same time, modulate APC function toward efficient priming of antigen-specific effector T cells. Selected cytotoxic agents may revert APC dysfunction either by directly maturing DCs or through induction of immunogenic tumor cell death. Furthermore, specific cytotoxic agents may support adaptive immunity by selectively depleting regulatory subsets, such as Tregs or myeloid-derived suppressor cells. Perspectively, this will allow developing effective combination strategies with novel immunotherapies to exert complementary pressure on tumors via direct toxicity as well as immune activation. We, here, review our current knowledge on the capacity of anti-cancer drugs to modulate APC functions to promote durable anti-cancer immune responses.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据